{content}

Study list

CoCo

Belgium
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

Andreasson

Sweden
|
2021-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition
  • Blood sample

Harrall

United Kingdom
|
2021-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

UKILD-Long COVID

United Kingdom
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

Yildiz

Türkiye
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

PL-PC19

Italy
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Dietary
  • Lifestyle

Dierckx

Belgium
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

Vicente-Valor

Spain
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir

LC-cohort

Finland
|
2021-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

LCV

Italy
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

Huygens

The Netherlands
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

POSTCODE

United Kingdom
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

BronchSTART

United Kingdom Ireland
|
2021-2026
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Emergency department
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Azevedo

Portugal
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition

MEADOWSPRING

Argentina Belgium Brazil Denmark Germany Mexico Romania Switzerland Turkiye Ukraine
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

Peghetti

Italy
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Rehabilitation

BRAINSTORM

France
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

Lindsay

United Kingdom
|
2021
  • Adults (18-64 years)
  • Fragile population
  • SARS-CoV-2
  • Post COVID-19 condition

Post-Covid UKF

Germany
|
2021
  • Adults (18-64 years)
  • General population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

SubFSC19-KN

Germany
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

LUNGTERMcov

Switzerland
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition

COMEBAC 2

France
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

Ballmann

Germany
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

Hedman

Sweden
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition